Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Long-Term Investments: 2016-2023

Historic Long-Term Investments for Seres Therapeutics (MCRB) over the last 8 years, with Dec 2023 value amounting to $1.4 million.

  • Seres Therapeutics' Long-Term Investments changed negligibly% to $1.4 million in Q1 2024 from the same period last year, while for Mar 2024 it was $1.4 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $1.4 million for FY2023, which is negligibly% changed negligibly from last year.
  • According to the latest figures from FY2023, Seres Therapeutics' Long-Term Investments is $1.4 million, which was down 0.00% from $1.4 million recorded in FY2022.
  • Over the past 5 years, Seres Therapeutics' Long-Term Investments peaked at $49.8 million during FY2020, and registered a low of $1.4 million during FY2019.
  • Over the past 3 years, Seres Therapeutics' median Long-Term Investments value was $1.4 million (recorded in 2023), while the average stood at $1.4 million.
  • As far as peak fluctuations go, Seres Therapeutics' Long-Term Investments skyrocketed by 3,458.93% in 2020, and later plummeted by 97.19% in 2021.
  • Seres Therapeutics' Long-Term Investments (Yearly) stood at $1.4 million in 2019, then spiked by 3,458.93% to $49.8 million in 2020, then tumbled by 97.19% to $1.4 million in 2021, then remained steady at $1.4 million in 2022, then remained steady at $1.4 million in 2023.